Full Press Release Details
WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQFormat: Fireside ChatDate: Tuesday, May 19Time: 11:00 – 11:30 a.m. ET
Jefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Thursday, June 4Time: 2:35 – 3:05 p.m. ET
The live webcasts will be accessible via the “Investors & Media” section of the Climb Biowebsite. Webcast replays will be available on the Climb Bio website beginning approximately two hours after each webcast event and will be archived for at least 30 days.
About Climb Bio, Inc.Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody in development for IgA nephropathy. For more information, please visitclimbbio.com.